Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)-Reference-Cited by-同舟云学术

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Published:2017-10-20 Issue:10 Volume:12 Page:e0186043
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Harter Philipp^ORCID,Hauke Jan,Heitz Florian,Reuss Alexander,Kommoss Stefan,Marmé Frederik,Heimbach André,Prieske Katharina,Richters Lisa,Burges Alexander,Neidhardt Guido,de Gregorio Nikolaus,El-Balat Ahmed,Hilpert Felix,Meier Werner,Kimmig Rainer,Kast Karin,Sehouli Jalid,Baumann Klaus,Jackisch Christian,Park-Simon Tjoung-Won,Hanker Lars,Kröber Sandra,Pfisterer Jacobus,Gevensleben Heidrun,Schnelzer Andreas,Dietrich Dimo,Neunhöffer Tanja,Krockenberger Mathias,Brucker Sara Y.,Nürnberg Peter,Thiele Holger,Altmüller Janine,Lamla Josefin,Elser Gabriele,du Bois Andreas,Hahnen Eric,Schmutzler Rita

Funder

Astra Zeneca Germany

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study;M Sant;Eur J Cancer,2015

2. Cancer statistics, 2016;RL Siegel;CA Cancer J Clin,2016

3. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;A du Bois;J Natl Cancer Inst,2003

4. Bevacizumab in the treatment of ovarian cancer;F Heitz;Adv Ther,2012

5. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy;LC Hanker;Ann Oncol,2012

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families;Journal of Personalized Medicine;2024-08-16

2. Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer;JCO Global Oncology;2024-06

3. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System;BMC Cancer;2024-04-19

4. Implementing mainstream genetic counseling within the area‐wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC‐HBOC): Satisfaction of primary care providers with the provided state‐of‐the‐art training by the Cologne Center;Journal of Genetic Counseling;2024-02

5. Neue therapeutische und supportive Optionen beim Ovarialkarzinom;Deutsche Zeitschrift für Onkologie;2023-12